Home
Resources
Publications
[Role of Angiotensin II Receptor Antagonists in the Treatment of Metabolic Syndrome]

[Role of Angiotensin II Receptor Antagonists in the Treatment of Metabolic Syndrome]

J I Botella Carretero, J Fresneda Moreno, L Manzano Espinosa

Rev Clin Esp. 2006 Jun;206(6):284-8.

PMID: 16762293

Abstract:

The metabolic syndrome, defined as the association of abdominal obesity, insulin resistance, dyslipidemia and hypertension, is a very prevalent disorder. Moreover, it identifies patients with a high cardiovascular risk, and when diagnosed, life style modifications and/or drug therapy can be initiated in these patients with the aim to reduce their cardiovascular risk. In the last few years, there has been much interest on drugs that lower insulin resistance, a central component of the metabolic syndrome as well as drugs that interrupt the renin-angiotensin system (achieved by angiotensive converting enzyme inhibitors and angiotensin II receptor blockers), due to their beneficial metabolic effects. Of special interest are the so-called selective PPARg modulators, such as telmisartan or the nTZDpa compound. In the future, they may show important benefits in the treatment of patients with the metabolic syndrome.

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP118414598	nTZDpa		118414-59-8	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: